IRCT20210915052492N1 IRCT 2021-10-11 Tehran University of Medical Sciences Subcutaneous octreotide therapy for malignant pleural effusion after pleurodesis with talc powder: A placebo-controlled, triple-blind, randomized trial Subcutaneous octreotide therapy for malignant pleural effusion after pleurodesis with talc powder: A placebo-controlled, triple-blind, randomized trial 2020-03-01 anticipated 46 Complete https://irct.ir/trial/58776 interventional Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The patients were randomized and allocated into two equal groups with a ratio of 1:1 and a block size of 4. A specific random code was created using Microsoft Office Excel and given to each patient, Blinding description: Allocated drugs were presented by these codes, so their relationships were kept confidential and were not revealed until the end of the study. Distinct individuals performed randomization, assessment, drug administration, and data entry. Octreotide and placebo ampules were indistinguishable regarding their shape and color. The patients, researchers, and statisticians were blinded to drug allocations. 3 Malignant pleural effusion. Intervention 1: Intervention group: Patients in the octreotide group received 50-microgram subcutaneous injections of octreotide acetate (Novartis, Switzerland) three times/day for up to 5 days prior to the pleurodesis. When the chest tube discharge declined to less than 150 cc per day, the patient underwent pleurodesis with talc using pleuroscopy. Intervention 2: Control group: Patients in the placebo group underwent the exact treatment and surgery protocols but received subcutaneous injections of NaCl 0.9% instead of octreotide. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is Not decided